Russell Hausfeld / TruthdigJan 11, 2024
The pioneering psychedelics advocacy group has traded its “public benefit model” for one closer to traditional pharma. Dig deeper ( 3 Min. Read )
Join our newsletterStay up to date with the latest from Truthdig. Join the Truthdig Newsletter for our latest publications.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, please login or create a user profile.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, upgrade to supporter.